Translational Development Acquisition Corp. Financial Summary

Quick Answer

Translational Development Acquisition Corp. reported Net Income of $6.36 million for fiscal year 2025.

Translational Development Acquisition Corp. — Key Financials by Year

Metric 2025 2024 2023 2022
Net Income $6.36M
+9059.7%
-$71.0K
+85.4%
-$485.6K
Total Assets $181.70M
+3.8%
$175.00M
+8659008.3%
$2.0K
Cash and Equivalents $29.8K
-93.2%
$438.2K
+21581.0%
$2.0K
Stockholders Equity -$6.54M
-16.9%
-$5.60M
-1002.6%
-$507.7K
-2196.3%
-$22.1K
Operating Income -$944.5K
-381.0%
-$196.4K
+59.6%
-$485.6K
Shares Outstanding 0 0

Most Recent Quarter

Metric Quarter Ending Value YoY QoQ
Net Income September 30, 2025 $1.66M +2808.9% +2.3%
Total Assets September 30, 2025 $179.98M +1.0%
Cash and Equivalents September 30, 2025 $47.1K +33.7%
Stockholders Equity September 30, 2025 -$6.38M -1018.0% -3.5%
Operating Income September 30, 2025 -$213.7K -248.6% +3.4%
  • Translational Development Acquisition Corp. reported Net Income of $6.36 million for fiscal year 2025.
  • Translational Development Acquisition Corp. showed an increase of +9059.7% in Net Income compared to the prior fiscal year.
  • Translational Development Acquisition Corp. reported Total Assets of $181.70 million for fiscal year 2025.
  • Translational Development Acquisition Corp. showed an increase of +3.8% in Total Assets compared to the prior fiscal year.
  • Translational Development Acquisition Corp. reported Cash and Equivalents of $29.8 thousand for fiscal year 2025.
  • Translational Development Acquisition Corp. showed a decrease of -93.2% in Cash and Equivalents compared to the prior fiscal year.
  • Translational Development Acquisition Corp. reported Stockholders Equity of -$6.54 million for fiscal year 2025.
  • Translational Development Acquisition Corp. showed a decrease of -16.9% in Stockholders Equity compared to the prior fiscal year.
  • Translational Development Acquisition Corp. reported Operating Income of -$944.5 thousand for fiscal year 2025.
  • Translational Development Acquisition Corp. showed a decrease of -381.0% in Operating Income compared to the prior fiscal year.
  • Translational Development Acquisition Corp. reported Shares Outstanding of 0 shares for fiscal year 2024.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment